Meta-analysis of 701 published cases of sinonasal neuroendocrine carcinoma: The importance of differentiation grade in determining treatment strategy

Laan, Tom P. van der; Iepsma, Rene S.; Witjes, Max J. H.; Laan, Bernard F.A.M. van der; Plaat, Boudewijn E. C.; Halmos, György B.

doi:10.1016/j.oraloncology.2016.10.002

Cited by 72 publications

(89 citation statements)

References 145 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More specifically, we found no prognostic difference between surgical approach or CRT as locoregional curative therapy. This is not in line with the literature data, [31][32][33] in which trimodality seems to be associated with better outcome in locoregional advanced cases. However, one should always consider the biases of treatment selection, which prompted a nonsurgical approach in diseases obtaining a favorable response to IC, thus bearing a better prognosis as recently reported by a retrospective U.S. series of SNUC.…”

Section: Discussioncontrasting

confidence: 92%

Locally advanced epithelial sinonasal tumors: The impact of multimodal approach

et al. 2019

View full text Add to dashboard Cite

Objective Outcomes of locally advanced epithelial sinonasal cancers remain unsatisfactory; moreover, only limited and heterogeneous data exist on prognostic factors. Methods We reviewed all consecutive patients with American Joint Committee Cancer stage III to IV epithelial sinonasal cancers treated with platinum‐based induction chemotherapy (IC) followed by locoregional treatment between 1996 and 2015. Results We identified 69 patients treated with a multimodal approach (IC, surgery, radiotherapy). Overall, 44 patients recurred (64%). Of those, 19 patients received salvage surgery, but only four remained disease‐free. Median overall survival (OS) was 62.5 months. Sinonasal neuroendocrine and small cell histotypes (P = 0.0085), neuroendocrine differentiation (P = 0.006), and lack of response to IC (P = 0.03) were associated with worse OS. In patients who recurred, median OS was 13 months since recurrence. Survival was longer in patients submitted to salvage surgery (44%) than in those receiving chemotherapy alone at recurrence (29.5 vs. 4.6 months). Patients with a clinical benefit after palliative chemotherapy had a longer median OS than those with disease progression (29.2 vs. 4.4 months; P < 0.0001). Conclusion Globally, the prognosis of locally advanced epithelial sinonasal cancers is dismal, with worse outcomes for neuroendocrine lesions. In the recurrent setting, feasibility of salvage surgery and clinical benefit from palliative chemotherapy are associated with longer OS. A multimodal treatment strategy with IC seems to offer improved OS when compared with other retrospective series not employing such a therapeutic tool. Level of Evidence 4 Laryngoscope, 130:857–865, 2020

show abstract

Section: Discussioncontrasting

confidence: 92%

Locally advanced epithelial sinonasal tumors: The impact of multimodal approach

et al. 2019

View full text Add to dashboard Cite

show abstract

“…This study found a 5-year disease-specific survival of 46% for these 115 patients with sinonasal small cell carcinoma. The authors found a non-significant trend for improved disease-specific survival with the use of surgery, however, they did not stratify patients by stage [22]. In our subgroup analysis no survival benefit was found with the addition of surgery to radiotherapy and chemotherapy (p=0.96) in locally advanced sinonasal small cell carcinomas.…”

Section: Discussioncontrasting

confidence: 55%

“…The majority of these paranasal and nasal cavity tumors presented as locally advanced cancers. The other largest series examining sinonasal small cell carcinomas, published by van der Laa et al, included a cohort of 115 patients obtained from a meta-analysis of 701 published studies[22]. This study found a 5-year disease-specific survival of 46% for these 115 patients with sinonasal small cell carcinoma.…”

Section: Discussionmentioning

confidence: 99%

Small cell carcinoma of the head and neck: An analysis of the National Cancer Database

et al. 2017

View full text Add to dashboard Cite

Purpose/Objective(s) To evaluate treatment trends and overall survival of patients with small cell carcinoma of the head and neck region. Materials/Methods Patients from 2004–2012 were identified from the National Cancer Database. Patient demographics and overall survival were analyzed. Multivariable analysis was used to identify predictors of survival. Results Among 347,252 head and neck patients a total of 1,042 (0.3%) patients with small cell carcinoma were identified. 17% of patients were diagnosed as stage I/II, 61% as stage III/IVA/IVB and 22% as stage IVC disease. The distribution by anatomic site was 9% oral cavity, 12% oropharynx, 35% larynx, 4% hypopharynx, 10% nasopharynx and 30% nasal cavity and paranasal sinuses. The median overall survival by anatomical site was 20.8 months for oral cavity, 23.7 months for oropharynx, 17.9 months for larynx/hypopharynx, 15.1 months for nasopharynx and 36.4 months for nasal cavity primary tumors. On multivariable analysis across stage, patients with nasal cavity and paranasal sinuses tumors had the best survival and patients with nasopharynx primaries had the worst survival. In stage I/II patients, type of treatment delivered resulted in no overall survival difference (p=0.78). In patients with locally advanced disease, there was no difference in survival between those treated with combined surgery, radiotherapy and chemotherapy compared to those treated only with radiotherapy and chemotherapy (p=0.46). The addition of radiotherapy to chemotherapy in the metastatic setting did not result in improved survival (p=0.14). Conclusions Small cell carcinoma of the head and neck is a rare malignancy with a poor prognosis. The addition of surgery to radiotherapy and chemotherapy did not improve survival in patients with locally advanced disease.

show abstract

“…Both NEC and SNUC often present late with a poor outcome. However, 5‐year survival of NEC is considerably better than that of SNUC (70.2% vs 35.9%) . Frequently, the presenting complaint will include unilateral nasal obstruction, headache, and facial pain.…”

Section: Sinonasal Malignanciesmentioning

confidence: 99%

“…The 4 largest studies were Kuo et al., van der Laan et al., Reiersen et al., and Xu et al . Kuo et al .…”

Section: Sinonasal Malignanciesmentioning

confidence: 99%

ICAR: endoscopic skull‐base surgery

Wang

Zanation

Gardner

et al. 2019

Int Forum Allergy Rhinol

157

279

View full text Add to dashboard Cite

Background Endoscopic skull‐base surgery (ESBS) is employed in the management of diverse skull‐base pathologies. Paralleling the increased utilization of ESBS, the literature in this field has expanded rapidly. However, the rarity of these diseases, the inherent challenges of surgical studies, and the continued learning curve in ESBS have resulted in significant variability in the quality of the literature. To consolidate and critically appraise the available literature, experts in skull‐base surgery have produced the International Consensus Statement on Endoscopic Skull‐Base Surgery (ICAR:ESBS). Methods Using previously described methodology, topics spanning the breadth of ESBS were identified and assigned a literature review, evidence‐based review or evidence‐based review with recommendations format. Subsequently, each topic was written and then reviewed by skull‐base surgeons in both neurosurgery and otolaryngology. Following this iterative review process, the ICAR:ESBS document was synthesized and reviewed by all authors for consensus. Results The ICAR:ESBS document addresses the role of ESBS in primary cerebrospinal fluid (CSF) rhinorrhea, intradural tumors, benign skull‐base and orbital pathology, sinonasal malignancies, and clival lesions. Additionally, specific challenges in ESBS including endoscopic reconstruction and complication management were evaluated. Conclusion A critical review of the literature in ESBS demonstrates at least the equivalency of ESBS with alternative approaches in pathologies such as CSF rhinorrhea and pituitary adenoma as well as improved reconstructive techniques in reducing CSF leaks. Evidence‐based recommendations are limited in other pathologies and these significant knowledge gaps call upon the skull‐base community to embrace these opportunities and collaboratively address these shortcomings.

show abstract

Meta-analysis of 701 published cases of sinonasal neuroendocrine carcinoma: The importance of differentiation grade in determining treatment strategy

Cited by 72 publications

References 145 publications

Locally advanced epithelial sinonasal tumors: The impact of multimodal approach

Locally advanced epithelial sinonasal tumors: The impact of multimodal approach

Small cell carcinoma of the head and neck: An analysis of the National Cancer Database

ICAR: endoscopic skull‐base surgery

Contact Info

Product

Resources

About